Serotonergic (SSRIs/SSNRIs) drugs require a gradual patient acclimation for common ethical prescribing practices. This means that the initial titration and dose amount prescribing standard is far too high a milligram amount in all medication sub-classes/brands. Prescribing these drugs at 1/10 the current dose amount standard will cause an effect in which the patient has a longer period to understand the complexities of how the drug interacts with their bodily/neuro-system, improving the safety and efficacy of prescribing practices, further increasing the legitimacy of informed consent. Employing this mechanical device of vastly reducing the initial dose amount in the prescribing practice comes from the scientific understanding about why these drugs are standardly prescribed at these high dose amounts: for a quicker acclimation, and nothing more. There is research evidence in symbiotic agreement with patient experiences to reinforce that these high doses do not more greatly improve depressive symptoms that these drugs attempt to treat. These drugs will have the same long-term effectiveness using the prescribing methodology aforementioned.
This understanding is needed in professional clinical environments because these drugs are often prescribed to people who are not exhibiting any potential for immediate actionable harm to themselves or others. In these cases, there is strictly no reason to ever put a human on a dose amount that disallows them from making the choice to medicate consciously and autonomously.
Cymbalta — 5.2mg — 6 years — actively tapering | without clinician
0 Replies
Join the conversation
Sign in to share your experience and connect with others.